BackBristol-Myers Squibb Overview
Bristol-Myers Squibb Co.

Bristol-Myers Squibb Debt to Equity

Latest debt-to-equity ratio for Bristol-Myers Squibb: 1.93 — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Debt to Equity

1.93

Debt to Equity

1.93

Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.

Debt to Equity (Comparison Companies)

Loading

Debt to Equity History

Loading

Debt to Equity Comparison

Loading

Bristol-Myers Squibb (BMY) FAQ

As of the most recent data, BMY shows a debt-to-equity ratio of 1.93. That is above the Healthcare sector average of 0.27. Scroll down for historical charts and peer comparison views.

The Healthcare sector average debt-to-equity ratio is about 0.27. Bristol-Myers Squibb is at 1.93, which is higher that average. That is roughly 627.6% above the sector mean. Use the comparison chart on this page to see how BMY stacks up against individual peers as well.

Investors watch BMY's debt-to-equity ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Bristol-Myers Squibb's latest reading is 1.93. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.

Besides this debt-to-equity ratio page, Stockcircle has Bristol-Myers Squibb's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect debt-to-equity ratio (currently 1.93) with ownership activity and broader fundamentals.

The Healthcare average debt-to-equity ratio is about 0.27, while BMY is at 1.93. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.